menu search

KLDO / Kaleido Biosciences Shares Plunging To 52-Week Low, Read Why

Kaleido Biosciences Inc (NASDAQ: KLDO) has delivered formal notice to voluntarily delist its common stock from NASDAQ as the Company will stop all operations. The Company expects to file a Form 25 with the Securities and Exchange Commission by April 18 to effect the voluntary delisting. Read More
Posted: Apr 8 2022, 12:27
Author Name: Benzinga
Views: 092046

KLDO News  

Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes

By PennyStocks
April 13, 2022

Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes

Here's what you need to know about trading penny stocks on April 13th The post Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes  appeared more_horizontal

Kaleido Biosciences Shares Plunging To 52-Week Low, Read Why

By Benzinga
April 8, 2022

Kaleido Biosciences Shares Plunging To 52-Week Low, Read Why

Kaleido Biosciences Inc (NASDAQ: KLDO) has delivered formal notice to voluntarily delist its common stock from NASDAQ as the Company will stop all o more_horizontal

Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohn's and Colitis Congress

By GlobeNewsWire
January 21, 2022

Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohn's and Colitis Congress

LEXINGTON, Mass., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, more_horizontal

Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohn's and Colitis Congress

By GlobeNewsWire
January 21, 2022

Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohn's and Colitis Congress

LEXINGTON, Mass., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, more_horizontal

Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohn's and Colitis Congress

By GlobeNewsWire
January 21, 2022

Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohn's and Colitis Congress

LEXINGTON, Mass., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, more_horizontal


Search within

Pages Search Results: